Investment Banking2018-06-20T23:47:19+00:00

Overview

Laidlaw Capital Markets helps clients gain access to capital through the public markets. Our expertise includes specialized offerings such as:

  • IPOs
  • Follow-on and Secondary Offerings
  • Confidentially Marketed Follow-Ons, Registered Directs, PIPES, and Rights Offerings

Investment Banking Team

James P. Ahern
James P. AhernManaging Partner, Head of Capital Markets

Jim joined the firm in October of 2010, and focuses on arranging financings for both private and public companies, mainly within the healthcare vertical. Over Jim’s Laidlaw tenure, he has led or played an integral role in capital raises totaling $3 billion of transaction value. Moreover, he has strategically grown Laidlaw’s Capital Markets’ team, and overseen the firm’s significant market share expansion.
Outside of the firm, Mr. Ahern is on the Board of Overseers for the Massachusetts Bay Big Brothers Big Sisters Foundation. Jim is also Vice-Chair of the BBBS Annual Golf Outing, an event which raises nearly 1 million dollars annually for the foundation. An active supporter of his Alma Mater, The Northfield Mount Hermon School, Jim serves as President of the NMH Basketball Alumni Council for Excellence.
Matt Dormer
Matt DormerManaging Director - Healthcare Investment Banking

Matt Dormer joins Laidlaw & Co. (UK) Ltd. from Summer Street Research Partners. During his time at Summer Street he completed more than 40 transactions which raised over $1.5 billion for biotechnology, medical device, and healthcare IT companies. Matt formerly worked for Wellington Management Company in the portfolio advisor group and previously worked in the equity research group covering the biotechnology sector at Fulcrum Global Partners in New York City. Prior to his experience in equity research, Matt was a scientist for a start-up biotechnology company and a research associate and teaching fellow at Harvard University, where he conducted research on tumor suppressor genes. Matt graduated from Davidson College with a BS in biology and received an MBA in finance from Northeastern University

Investment Banking Advisory

Laidlaw is committed to partnering with organizations in an advisory capacity. Our team of bankers’ focus on the healthcare industry and the depth of their experience allows them to provide comprehensive knowledge of both the industry and the markets. Our team is able to help organizations strategize and navigate goals on an individual company basis. Whether one is seeking transactions such as acquisitions, divestitures, and mergers, or “going private” transactions and management-led buyouts, we have the resources, experience, and capabilities to work closely with clients to achieve the desired results.

All of our offerings

2018-05-14T13:55:01+00:00

MEI
Pharma

PIPE Transaction
Common Stock and Warrants
 

$75,000,000

Co-Placement Agent
May 2018

2018-05-17T20:34:24+00:00

Sesen
Bio

Registered Direct
Common Stock and
Warrants

$10,000,000

Exclusive Placement Agent
March 2018

2018-06-01T01:40:10+00:00


AIT Therapeutics

PIPE Transaction
Warrants
.

$9,820,154.54

Exclusive Placement Agent
February 2018

2018-05-04T14:37:33+00:00


Affimed

Follow-On Offering
Common Stock
 

$23,000,000

Financial Advisor
February 2018

2018-05-04T14:41:44+00:00

Cytori
Therapeutics

Rights Offering
Convertible Preferred
Stock and Warrants

$10,000,000

Financial Advisor
November 2017

2018-05-04T15:09:37+00:00

Onconova
Therapeutics

Registered Direct
Common Stock
 

$1,380,000

Sole Placement Agent
November 2017

2018-05-04T15:20:13+00:00

Repros
Therapeutics

Confidentially Marketed
Public Offering
Common Stock and Warrants

$3,000,000

Sole Book-Runner
May 2017

2018-05-04T15:27:52+00:00

Onconova
Therapeutics

Confidentially Marketed
Public Offering
Common Stock

$5,963,517

Sole Book Runner
April 2017

2018-05-04T15:34:41+00:00


BioSig Technologies

PIPE Transaction
Common Stocks
& Warrants

$4,349,954

Exclusive Placement Agent
March 2017

2018-05-04T15:28:33+00:00

Therapix
Biosciences

Initial Public Offering
Common Stock
 

$13,800,000

Sole Book Runner
March 2017

2018-05-04T15:28:47+00:00

Gemphire

PIPE Transaction
Common Stock & Warrants
 

$12,500,000

Co-Manager
March 2017

2018-05-04T15:32:10+00:00


AIT Therapeutics

PIPE Transaction,
Common Stock
and Warrants

$10,200,000

Placement Agent
March 2017

2018-05-04T15:32:33+00:00


Evoke Pharma

Confidentially Marketed
Follow-On
Common Stock

$8,050,000

Sole Book Runner
February 2017

2018-05-04T15:34:50+00:00


Medovex Corporation

PIPE Transaction
Common Stock & Warrants
 

$3,022,000

Exclusive Placement Agent
February 2017

2018-05-04T15:57:47+00:00

Medovex
Corporation

PIPE Transaction
Common Stock
& Warrants

$1,398,033

Placement Agent
April 2016

2018-05-04T15:48:50+00:00


ImmunoCellular

Follow-On Offering
Common Stocks
& Warrants

$7,400,000

Lead Manager
August 2016

2018-05-04T15:45:14+00:00


Gemphire

Initial Public Offering
Common Stock
 

$30,000,000

Co-Manager
August 2016

2018-05-04T15:46:19+00:00


PhaseRx

Initial Public Offering
Common Stock
 

$18,500,000

Book Runner
May 2016

2018-05-04T15:55:48+00:00

Aeolus
Pharmaceuticals

PIPE Transaction
Common Stock
& Warrants

$6,750,000

Exclusive Placement Agent
December 2015

2018-05-04T15:54:44+00:00


Cerecor, Inc.

Initial Public Offering
Common Stock
& Warrants

$26,000,000

Lead Manager
October 2015

2018-05-04T15:59:54+00:00

Sevion
Therapeutics

PIPE Transaction
Common Stocks
& Warrants

$7,325,217

Exclusive Placement Agent
July 2015

2018-05-04T16:00:52+00:00

Viking
Therapeutics

Initial Public Offering
Common Stock
 

$27,600,000

Sole Book-Runner
May 2015

2018-05-04T16:03:10+00:00


ADMA Biologics

Follow-On Offering
Common Stock
 

$9,800,000

Co-Manager
March 2015

2018-05-04T16:03:50+00:00

Medovex
Corporation

Initial Public Offering
Common Stock
& Warrants

$9,200,000

Sole Book-Runner
December 2014

2018-05-04T16:04:24+00:00

Cel-Sci
Corporation

Follow-On Offering
Common Stock
& Warrants

$7,000,000

Sole Book-Runner
October 2014

2018-05-04T16:05:31+00:00

Cel-Sci
Corporation

Follow-On Offering
Common Stock
& Warrants

$10,000,000

Joint Book-Runner
April 2014

2018-05-04T16:11:19+00:00

Cel-Sci
Corporation

Follow-On offering
Common Stock & Warrants
 

$3,000,000

Sole Book-runner
December 2013

2018-05-04T16:11:34+00:00


ADMA Biologics

Initial Public Offering
Common Stock
 

$28,347,500

Co-Manager
October 2013

2018-05-04T16:11:55+00:00

Cel-Sci
Corporation

Follow-On Offering
Common Stock
& Warrants

$17,826,087

Co-Manager
October 2013

2018-05-04T16:12:06+00:00

Relmada
Therapeutics

Convertible
Preferred Stock
& Warrants

$8,000,000

Placement Agent
September 2013

2018-05-04T16:12:39+00:00

Relmada
Therapeutics

Convertible Bridge
Notes & Warrants
 

$750,000

Placement Agent
September 2013

2018-05-04T16:12:58+00:00


Alliqua

Common Stock &
Warrants
 

$3,000,000

Co-Manager
July 2013

2018-05-04T16:13:03+00:00

BioSig
Technologies

Convertible
Preferred Stock
 

$2,800,000

Exclusive Placement Agent
July 2013